FBIOP NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Fortress Biotech Inc Pref Series A · Healthcare · Biotechnology

Open interactive chart View report data
Latest close 18.88 USD
-0.1% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 23.1% above the Trend Line and sits at 83.2% of its 52-week range. The latest completed week returned -0.1%, after a -7.5% four-week move. The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers. The latest news-sentiment score is 49/100. Near-term considerations: volume confirmation is below normal.

Setup score 65 out of 100
Latest Close 18.88 USD 31 Jul 2026
1W Return -0.1% latest completed week
4W Return -7.5% short-term follow-through
12W Return 39.8% quarterly tape
Trend Breadth 80.8% 42 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 31-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is positive on the latest completed week.
What could go wrong
  • 2 reversal markers appear in the recent smart-money tape.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -0.1% Latest completed week; four-week move -7.5%. Indicator stack 89/46 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Positive 55.33% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 49/100 52 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 23.1% above the Trend Line and sits at 83.2% of its 52-week range. The latest completed week returned -0.1%, after a -7.5% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.9412-week average 0.95

12-week confirmation

Trend active12/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.94Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers22 reversal markers

No recent accumulation markers. 2 reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -7.5% over four weeks, 39.8% over 12 weeks, and 172.6% over one year. The current trend has remained active for 31 consecutive weeks.

Performance by holding period

1W-0.1%
4W-7.5%
12W39.8%
26W54.8%
52W172.6%
Active trend streak31 weeks
Active weeks in one year42
Trend breadth80.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.16Latest activity-pressure read.
Pressure change-88.3%Four-week change in activity pressure.
Leadership44.62Latest relative-leadership reading.
RS change-25.2%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks strongly versus its universe; growth is moderate; valuation is inexpensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 94% Model confidence 89%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength100/100Blend of value, momentum, and quality. Underlying universe rank 1; rank 1 is best.
Value99/100Relative valuation strength. Underlying universe rank 2; rank 1 is best.
Quality85/100Profitability and accounting quality. Underlying universe rank 16; rank 1 is best.
Momentum98/100Medium-term price momentum. Underlying universe rank 3; rank 1 is best.
Growth75/100Revenue and earnings growth. Underlying universe rank 26; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
0.8x
Price divided by trailing earnings.
Price / sales
1.5x
Market value relative to trailing revenue.
EV / EBITDA
0.7x
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
155.5%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
64.5%
Gross profit retained from each unit of revenue.
Operating margin
215.9%
Operating profit retained from revenue.
Free-cash-flow margin
238.3%
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
14.5%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
0.5%
Cash dividends relative to market value.
Buyback yield
-14.1%
Net share repurchases relative to market value.
Shareholder yield
-13.6%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-1.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity1 / 0

1 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment49/100

Weighted news tone is neutral across 52 relevant articles.

4 positive · 43 neutral · 5 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-11.9%Distance below the 52-week high.
13-week volatility6.9%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher15 of 2611 weeks finished lower.
Best week+30.9%Week of 27 Feb.
Worst week-9.1%Week of 10 Jul.
Latest week-0.1%Week of 31 Jul.

Shape of recent returns

Strong gains6
Modest gains9
Flat weeks0
Modest losses7
Sharp losses4
Recent vol6.9%13-week weekly-return volatility.
Base vol8.0%52-week weekly-return volatility.
Up/down split33/19Count of positive and negative weeks in the 52-week window.
Average skew6.2% / -4.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape67/100

Trend, activity pressure, participation, and risk combine to a 67/100 tape read.

 Indicator analysis87/100

Latest 12-week confirmation: trend 12/12, activity pressure 12/12, relative leadership 12/12.

Activity pressure 0.94; 2 reversal markers Next-Week ExpectancyPositive 55.33%

Next-week expectancy is positive with a 55.33% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors94/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 88; Small Cap Core rank 8 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment49/100

Weighted news tone is neutral across 52 relevant articles.

Precision Trading with Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) Risk Zones Insiders1 / 0

1 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 202618.88 USD-0.1%15.34 USD10.46 USD0.1644.6259.9KOn
24 Jul 202618.89 USD1.0%15.05 USD10.43 USD0.4847.7237.9KOn
17 Jul 202618.71 USD0.8%14.74 USD10.40 USD0.7746.2436.6KOn
10 Jul 202618.56 USD-9.1%14.42 USD10.38 USD1.1341.02112.6KOn
3 Jul 202620.41 USD1.8%14.06 USD10.35 USD1.4159.6458.9KOn
26 Jun 202620.05 USD-0.0%13.62 USD10.32 USD1.5660.6646.6KOn
19 Jun 202620.06 USD-3.1%13.19 USD10.29 USD1.6555.84114.9KOn
12 Jun 202620.71 USD0.2%12.74 USD10.25 USD1.5067.38126.6KOn
5 Jun 202620.67 USD6.2%12.28 USD10.22 USD1.1873.15301.7KOn
29 May 202619.47 USD16.6%11.82 USD10.18 USD0.7057.79236.0KOn
22 May 202616.70 USD11.3%11.40 USD10.14 USD0.3141.06138.1KOn
15 May 202615.01 USD11.2%11.07 USD10.12 USD0.0529.92123.0KOn
8 May 202613.50 USD-5.9%10.80 USD10.12 USD-0.0817.6592.5KOn
1 May 202614.35 USD0.7%10.59 USD10.14 USD0.0132.8741.9KOn
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.